See the DrugPatentWatch profile for Ceritinib
When does ceritinib’s patent expire?
I don’t have enough source information here to state a specific expiry date for ceritinib’s patents. Patent expiry depends on multiple factors, including which country’s filings you mean (US, EU, UK, etc.), the specific patent(s) covering ceritinib (drug substance vs. formulation vs. method-of-use), and any extensions or regulatory exclusivities that apply in that jurisdiction.
To answer precisely, you need at least one of the following: the jurisdiction (e.g., US or EU) or a patent number (or application) to look up.
What determines ceritinib patent expiry dates (and why they differ by country)?
Ceritinib’s “patent expiry” can refer to different legal protections:
- Basic patent term for the specific patent family (varies by filing/priority dates).
- Patent term adjustments/extensions (can shift expiry in some jurisdictions).
- Regulatory exclusivities that can extend market protection even after a patent expires (these are jurisdiction-specific and distinct from patents).
- Multiple overlapping patents in the same product family, meaning the effective “blocking” date may be set by the last expiring relevant patent, not the first.
Because of this, two people asking “when does ceritinib’s patent expire?” may be referring to different patents or different jurisdictions.
How can you find the exact ceritinib expiry you’re looking for?
If you tell me the country (US vs EU/UK vs another) and ideally the company/patent family or a patent number, I can help you identify:
- which ceritinib patents are still in force,
- which one(s) drive market exclusivity,
- and the expected expiry timeline under that jurisdiction.
What happens if a patent expires but exclusivity still applies?
If a ceritinib patent expires, it does not automatically mean generics/biosimilars can launch. Even with patent expiry, companies may still be blocked by:
- other still-active patents in the same product family, or
- regulatory exclusivities (where applicable),
- and ongoing litigation or settlement agreements that can delay entry.
Next question to clarify so I can give a concrete date
Which jurisdiction do you mean (US, EU, UK, or another), and do you want the date for the first ceritinib patent expiry or the date when all key patents/exclusivities stop blocking generic entry?